Early drug test aims to tackle root cause of rare lung and liver disease
NCT ID NCT02363946
Summary
This early-stage study tested a new drug called ARC-AAT in healthy volunteers and people with Alpha-1 Antitrypsin Deficiency (AATD). The main goal was to check if the drug was safe and to see if a single dose could lower the levels of a harmful protein in the blood that causes lung and liver damage in AATD. The study was terminated, and it was not designed to see if the drug improves symptoms or is a cure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site 1
Melbourne, Victoria, 3004, Australia
-
Research Site 2
Homburg, Germany
-
Research Site 3
Leiden, 2333ZA, Netherlands
-
Research Site 4
Edgbaston, Birmingham, B15 2WB, United Kingdom
Conditions
Explore the condition pages connected to this study.